Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards ...

For years, medtech companies have treated the digital experience around their devices as an afterthought. A layer of software ...

A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low platelet counts (thrombocytopenia) caused by chemotherapy for solid tumours. The ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...

After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, said to be the biggest science lab of its kind in the UK. The Discovery Centre (DISC ...